Evidence outlook
Approved: Rheumatoid Arthritis, Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Large B-Cell Lymphoma, Relapsed/Refractory Non-Hodgkin Lymphoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Reliable signal
Also approved (3)
- Granulomatosis with polyangiitis (GPA) (Wegener's granulomatosis) and microscopic polyangiitis (MPA) in adults, in combination with glucocorticoids
- Moderate to severe pemphigus vulgaris (PV) in adults
- Ruxience (rituximab): NHL, CLL, rheumatoid arthritis, GPA/MPA, pemphigus vulgaris
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
REFLECTIONS B328-06 NCT02213263 · Follicular Lymphoma The trial randomized 394 participants to PF-05280586 or active comparator MabThera and was double-blind. The primary endpoint was the clinical response rate at Week 26, and the prespecified equivalence margin was met because the 95% confidence interval for the response-rate difference (-4.16% to 13.47%) remained within the -16% to 16% limits. Registry: NCT02213263 | 3 | Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 2017-10-23 | Overall Response Rate (ORR): Percentage of Participants With Overall Response (OR) at Week 26 (Week 26): Rituximab-EU 70.7 percentage of participants (95% CI 63.8 to 76.9) | PF-05280586 75.5 percentage of participants (95% CI 68.9 to 81.4) | Reliable signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2 (1)
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other CD20 drugs
Obinutuzumab, Ocrelizumab, Ocrevus Zunovo, Ofatumumab, Rituximab and 10 more. Compare all 16 CD20 drugs
This mechanism is crowded: 15 other tracked programmes target it, none of them ahead of this one.
This drug's own stage for B-Cell Non-Hodgkin Lymphoma: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| PF-05280586: this drug | Approved | Biologic (subtype unspecified) | CD20 | not yet graded | No reviewed efficacy summary in this indication | |
| Ocrelizumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ocrevus Zunovo | Approved(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Ofatumumab | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Ublituximab (Briumvi) | Approved(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| ABP 692 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| BCD-281 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| CT-P53 | Phase 3(overall) | Monoclonal antibody | CD20 | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| Divozilimab (Ivlizi) | Phase 3(overall) | Monoclonal antibody | CD20 | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Odronextamab | Phase 3 | Multispecific antibody | CD20 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Surovatamig | Phase 2 | Multispecific antibody | CD19 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| AZD4512 | Phase 1/2 | Antibody–drug conjugate | CD22 | not yet graded | No reviewed efficacy summary in this indication | |
| JNJ-88998377 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5837 | Phase 1 | Multispecific antibody | CD22 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| SHR-3079 | Phase 1 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Vispacabtagene Regedleucel | Discontinued | Cell therapy | CD19 | not yet graded | No reviewed efficacy summary in this indication |
Compare side by side
1 further pair is tracked; the rosters on each shared mechanism and indication page list every rival in the race.
Upcoming events
No upcoming readouts on record for this asset.